The ProstatID tool uses artificial intelligence with traditional MRI scanning to save time and cost in the detection of lesions
Bot Image receives FDA clearance for AI-based detection and diagnosis of prostate cancer. (Credit: Dmitriy Gutarev from Pixabay)
US-based MRI medical device company Bot Image has received approval from the US Food and Drug Administration (FDA) for artificial intelligence software, ProstatID, used in the detection and diagnosis of prostate cancer.
Bot Image’s AI-driven medical device CAD software is intended to improve the accuracy and speed of prostate cancer detection (CADe) and diagnosis (CADx).
The ProstatID tool uses artificial intelligence with traditional MRI scanning to save time and cost in the detection of lesions.
The software’s algorithm recognises and measures the volume of the prostate gland, detects suspicious cancerous lesions, and assigns a cancer probability to each one.
It also suggests a diagnostic case score known as a PI-RADS (Prostate Imaging Reporting and Data System) score.
The algorithm was trained by analysing thousands of MRI image sets, radiological interpretations, guided biopsies, and pathology lab results, said the firm.
According to Bot Image, the software has shown significant time and money saving for the patient and the practitioner and saving lives through early and precise detection.
The capabilities of ProstatID include segmentation of a patient’s prostate and improving on-screen formatting of prostate MRI cases.
The computer-aided design tool, which is currently offered as a Software-as-a-Service (SaaS) product can be used via a secure VPN tunnel connection between the MRI system or radiology department server and the cloud-based ProstatID server.
Both the software and connectivity abide by HIPAA regulations and maintain data security.
Bot Image founder and CEO Dr Randall Jones said: “Prostate cancer screening and detection methods adoption has changed little over the past 30 years, despite the mountain of evidence pointing to the efficacy of superior technologies and the futility of the old methods.
“Sadly, this has resulted in the unnecessary and premature deaths of countless numbers of men in the US alone. ProstatID represents an exciting step in the fight to save lives.”
Jones added: “With FDA clearance, the path for implementation is open and hospitals and radiological clinics can connect in as little as one hour of IT effort, and begin bringing this exciting technology to their patients.”